Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which shock works best for AFib? new trial pits zoll vs lifepak

NCT ID NCT05992623

Disease control Sponsor: Inova Health Care Services Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two different defibrillator waveforms—Zoll's 200J rectilinear biphasic shock and Lifepak's 360J biphasic truncated exponential shock—to see which restores normal heart rhythm better in people with atrial fibrillation. Over 500 adults were randomly assigned to receive one type of shock during a cardioversion procedure. The main goal was to compare how many patients had a normal heartbeat one minute after the first shock, and also to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
external defibrillator (Zoll or Lifepak)
What this could lead to
If one waveform proves more effective, hospitals may adopt it to improve success rates for restoring normal heart rhythm with fewer shocks.
What could go wrong
This is a completed, moderate-sized trial, but results may not apply to all patients or settings. Both shocks are already in use, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

546 people

The number who actually took part.

Started

Jul 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. In AF on presentation with plan for DCCV in either the Electrophysiology lab or DCCV procedure area Exclusion Criteria: 1. Participants who are receiving any other investigational agents. 2. Parents/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures. 3. Patients with arrhythmias other than AF 4. Patients with hemodynamically unstable AF 5. Patients with untreated hyperthyroidism 6. Patients with known or suspected pregnancy 7. Patients without sufficient anticoagulation or a transesophageal echocardiogram or computed tomography scan documenting the absence of intracardiac thrombi

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Inova Health System

    Falls Church, Virginia, 22042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.